Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor‐induced hypercoagulability in vitro and in vivo

Calibrated Automated Thrombin Generation Measurement in Clotting Plasma

H.C. Hemker, Peter Giesen, Raed Al Dieri et al. · Pathophysiology of Haemostasis and Thrombosis · 2003 · 1.4K citations · Full text

Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism

Sam Schulman, Clive Kearon, Ajay K. Kakkar et al. · New England Journal of Medicine · 2013 · 977 citations · Full text

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

S. Bertil Olsson · The Lancet · 2003 · 810 citations

Thrombosis, Ischemic Stroke, Cardiovascular Disease +11

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor

Elisabeth Perzborn, Andreas Wilmen, Jens Pohlmann et al. · Journal of Thrombosis and Haemostasis · 2005 · 583 citations · Full text

Molecular Pharmacology, Thrombosis, Vivo Studies +9

Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

Stefan H. Hohnloser, Jonas Oldgren, Sean Yang et al. · Circulation · 2012 · 349 citations · Full text